('e-Therapeutics' or 'the Company')

First Day of Dealings on AIM

A placing of 1,985,075 Ordinary Shares at 67 pence each has raised 1.33 million
(gross) for the Company. The total issued share capital of the Company is
55,710,103 and the market capitalisation of the Company at the Placing Price
following Admission will be 37.33 million.

Commenting on the Placing and Admission, Professor Malcolm Young, Chief
Executive Officer of e-Therapeutics, said: 'We are delighted by the response of
investors to the flotation of e-Therapeutics. The funds raised will enable us to
develop and broaden our drug development pipeline, and will significantly raise
the profile of e-Therapeutics with potential licensing partners. I would like to
thank all of our investors for recognising the exciting opportunity that lies
ahead.'

Came across this audio interview with E- THERAPEUTICS.

Take a look:

http://www.brrmedia.co.uk/event/98793/daniel-elger-chief-financial-officer